• § 360bbb. Expanded access to unapproved therapies and diagnostics

• § 360bbb-0. Expanded access policy required for investigational drugs

• § 360bbb-0a. Investigational drugs for use by eligible patients

• § 360bbb-1. Dispute resolution

• § 360bbb-2. Classification of products

• § 360bbb-3. Authorization for medical products for use in emergencies

• § 360bbb-3a. Emergency use of medical products

• § 360bbb-3b. Products held for emergency use

• § 360bbb-3c. Expedited development and review of medical products for emergency uses

• § 360bbb-4. Countermeasure development, review, and technical assistance

• § 360bbb-4a. Priority review to encourage treatments for agents that present national security threats

• § 360bbb-4b. Medical countermeasure master files

• § 360bbb-5. Critical Path Public-Private Partnerships

• § 360bbb-5a. Emerging technology program

• § 360bbb-6. Risk communication

• § 360bbb-7. Notification

• § 360bbb-8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments

• § 360bbb-8a. Optimizing global clinical trials

• § 360bbb-8b. Use of clinical investigation data from outside the United States

• § 360bbb-8c. Patient participation in medical product discussion

• § 360bbb-8d. Notification, nondistribution, and recall of controlled substances